Mereo BioPharma Group plc

MREO Nasdaq SEC CIK 1719714
Follow Mereo BioPharma Weekly email: filings, results

Financials

Reported figures only · latest: fiscal 2022 GBP · IFRS
Net income −£34.2M
EPS, diluted −£0.06 −400% vs prior year
Operating cash flow −£38.8M −641% vs prior year
Operating income −£43.6M −108.1% vs prior year
Net income by fiscal year
−£38.8M
−£32M
−£34.8M
−£163.6M
−£34.2M
FY17 FY18 FY19 FY20 FY22

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, IFRS
Revenue and net income8 fiscal years
−£200M−£150M−£100M−£50M£0FY15FY16FY17FY18FY19FY20FY21FY22
Show the numbers
YearNet income
FY22−£34.2M
FY21-
FY20−£163.6M
FY19−£34.8M
FY18−£32M
FY17−£38.8M
FY16−£28.4M
FY15-
Free cash flowOperating cash flow minus capital expenditure
−£60M−£40M−£20M£0FY15FY16FY17FY18FY19FY20FY21FY22
Show the numbers
YearFree cash flow
FY22−£38.8M
FY21−£5.8M
FY20−£28.4M
FY19−£46M
FY18−£23.2M
FY17−£32.2M
FY16−£29.7M
FY15-